Novo Nordisk Named And Shamed For Paying Pharmacists To Boost Weight Loss Drug Sales
Training Scheme Was Disguised Promotion, UK Watchdog Finds
The company has been publicly reprimanded for its training program for UK pharmacists, which the industry watchdog judged to be solely focused on increasing use of weight loss drug Saxenda
You may also be interested in...
The Danish firm’s GLP-1 receptor agonist triggered significant weight loss in a Phase III trial in obese teenagers, sparking filing plans that could strengthen the product’s market share even as rival Eli Lilly mounts a threat with Mounjaro.
The GLP-1/GIP agonist tirzepatide is a key addition to Lilly’s commercial portfolio as the company leans on new products to deliver on volume-driven growth through the current decade.
Roche remains the European sector’s biggest company despite a wobble in 2022, but Novo Nordisk’s spectacular growth has seen it overtake AstraZeneca and Novartis in market cap terms.